Myostatin Propeptide

The N-terminal propeptide of myostatin that naturally maintains myostatin in an inactive latent complex. When administered exogenously, it binds to and inhibits mature myostatin with high specificity, offering a more targeted approach to myostatin inhibition compared to broader TGF-beta pathway blockers like ACE-031 or Follistatin.

• Binds directly to the mature myostatin dimer, forming an inactive latent complex
• Prevents myostatin from engaging ActRIIB receptors on muscle fibers
• Highly specific — does not significantly inhibit activin, GDF-11, or BMPs
• Relieves Smad2/3-mediated transcriptional repression of muscle-specific genes

• Active malignancy
• Pregnancy or breastfeeding
• Known hypersensitivity to recombinant proteins

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 7 days. Highly sensitive to degradation at room temperature.

The myostatin propeptide has been extensively studied in animal models. Transgenic mice overexpressing the propeptide exhibit 20-40% increases in muscle mass. Engineered variants with enhanced affinity (e.g., D76A mutant) show even greater efficacy. While no direct clinical trials of the injectable peptide exist, gene therapy approaches delivering the propeptide are in preclinical development for muscular dystrophies.